| Year |
Citation |
Score |
| 2022 |
Prasad NK, Seiple IB, Cirz RT, Rosenberg OS. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrobial Agents and Chemotherapy. e0005422. PMID 35471042 DOI: 10.1128/aac.00054-22 |
0.363 |
|
| 2020 |
Bulman ZP, Cirz R, Hildebrandt D, Kane T, Rosario Z, Wlasichuk K, Park M, Andrews LD. Unraveling the gentamicin drug product complexity reveals variation in microbiological activities and nephrotoxicity. Antimicrobial Agents and Chemotherapy. PMID 32601158 DOI: 10.1128/Aac.00533-20 |
0.333 |
|
| 2019 |
Krause KM, Haglund CM, Hebner C, Serio AW, Lee G, Nieto V, Cohen F, Kane TR, Machajewski TD, Hildebrandt D, Pillar C, Thwaites M, Hall D, Miesel L, Hackel M, ... ... Cirz RT, et al. Potent LpxC Inhibitors with Activity Against Multi-Drug Resistant . Antimicrobial Agents and Chemotherapy. PMID 31451507 DOI: 10.1128/Aac.00977-19 |
0.481 |
|
| 2019 |
Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, ... Cirz R, et al. Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase. Journal of Medicinal Chemistry. PMID 31306011 DOI: 10.1021/Acs.Jmedchem.9B00625 |
0.524 |
|
| 2019 |
Cohen F, Aggen JB, Andrews LD, Assar Z, Boggs J, Choi T, Dozzo P, Easterday AN, Haglund CM, Hildebrandt DJ, Holt MC, Joly K, Jubb A, Kamal Z, Kane TR, ... ... Cirz RT, et al. -Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety. Chemmedchem. PMID 31283109 DOI: 10.1002/cmdc.201900287 |
0.34 |
|
| 2017 |
Wagman AS, Cirz R, McEnroe G, Aggen J, Linsell MS, Goldblum AA, Lopez S, Gomez M, Miller G, Simons LJ, Belliotti TR, Harris CR, Poel TJ, Melnick MJ, Gaston RD, et al. Synthesis and Microbiological Evaluation of Novel Tetracyclic Fluoroquinolones. Chemmedchem. PMID 28881459 DOI: 10.1002/Cmdc.201700426 |
0.339 |
|
| 2016 |
Laponogov I, Pan XS, Veselkov DA, Cirz RT, Wagman A, Moser HE, Fisher LM, Sanderson MR. Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Open Biology. 6. PMID 27655731 DOI: 10.1098/Rsob.160157 |
0.401 |
|
| 2016 |
Heine HS, Chuvala L, Riggins R, Cirz R, Cass R, Louie A, Drusano GL. Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice. Antimicrobial Agents and Chemotherapy. 60: 1834-40. PMID 26824958 DOI: 10.1128/Aac.02887-15 |
0.316 |
|
| 2014 |
Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A. Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. The Journal of Infectious Diseases. 210: 1319-24. PMID 24760199 DOI: 10.1093/Infdis/Jiu237 |
0.403 |
|
| 2007 |
Roberts TC, Smith PA, Cirz RT, Romesberg FE. Structural and initial biological analysis of synthetic arylomycin A2. Journal of the American Chemical Society. 129: 15830-8. PMID 18052061 DOI: 10.1021/Ja073340U |
0.671 |
|
| 2007 |
Cirz RT, Romesberg FE. Controlling mutation: intervening in evolution as a therapeutic strategy. Critical Reviews in Biochemistry and Molecular Biology. 42: 341-54. PMID 17917871 DOI: 10.1080/10409230701597741 |
0.676 |
|
| 2007 |
Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN, Romesberg FE. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. Journal of Bacteriology. 189: 531-9. PMID 17085555 DOI: 10.1128/Jb.01464-06 |
0.706 |
|
| 2006 |
Cirz RT, O'Neill BM, Hammond JA, Head SR, Romesberg FE. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. Journal of Bacteriology. 188: 7101-10. PMID 17015649 DOI: 10.1128/Jb.00807-06 |
0.675 |
|
| 2006 |
Cirz RT, Gingles N, Romesberg FE. Side effects may include evolution. Nature Medicine. 12: 890-1. PMID 16892033 DOI: 10.1038/Nm0806-890 |
0.687 |
|
| 2006 |
Cirz RT, Romesberg FE. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrobial Agents and Chemotherapy. 50: 220-5. PMID 16377689 DOI: 10.1128/Aac.50.1.220-225.2006 |
0.709 |
|
| 2005 |
Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE. Inhibition of mutation and combating the evolution of antibiotic resistance. Plos Biology. 3: e176. PMID 15869329 DOI: 10.1371/Journal.Pbio.0030176 |
0.718 |
|
| Show low-probability matches. |